News

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet.

A new approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models.

During development in the womb, immune cells called macrophages go to the kidneys, and they remain there for life. Understanding the possible healing role for these macrophages after kidney damage may be crucial to helping treat patients who suffer acute kidney injury.

Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.

This new vaccine reduced the malaria-causing parasite’s release from the liver and into the blood of infected rhesus macaques by 75 to 80 percent at the Oregon National Primate Research Center at OHSU.

Researchers around the world are on the search for new therapies – so far in vain. An interdisciplinary team from the fields of structural biology, immunology and cell biology has now, for the first time, successfully produced a protein that could balance the overshooting immune response.

Scientists have identified a protein which is associated with more aggressive breast, colorectal and ovarian cancers, which could be used to assist the diagnosis and development treatments for these cancers.

Scientists find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions.

A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies.

Preclinical detection of prions has proven difficult, but new research suggests skin samples hold early signs of prion disease that precede neurologic symptoms.